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BACKGROUND  
Lung carcinoma constitutes 11% of all cases of carcinomas and it constitutes 
around 13% of all cancer related mortality. Most of the lung carcinomas are in advanced 
stage at presentation. So the surgical cure rate is very low, probably less than 10% of 
cases. Targeted therapy remains the mainstay of treatment in such cases.  This study aims 
to analyze the distribution of Lung carcinomas in relation to age, gender and site and their 
histopathological classification based on differentiation and Epidermal Growth Factor 
Receptor (EGFR) expression. Immunohistochemical evaluation of Epidermal Growth 
Factor Receptor (EGFR) expression is a cost effective tool for targeted therapy.  
 METHODS:  
The study was carried out in the Department of Pathology, Madurai Medical 
College, Madurai, during the period from July 2015 to August 2017 on 108 specimens of 
lung biopsies received in the department after exclusion of benign lesions. After adequate 
fixation, specimens were processed and stained with Haematoxylin and Eosin. The cases 
were histologically classified based on WHO classification, 2015. Selected cases of lung 
carcinomas were subjected to immunohistochemical evaluation with Epidermal Growth 
Factor Receptor (EGFR) marker study. Spearman’s Rho and Pearman’s correlation 
coefficients were calculated to determine the strength of correlation between the 
histologic grade and EGFR expression. The observations were compared with other 
studies and inferences drawn. 
 
 RESULTS:  
Lung carcinomas constitute about 2.3% of all neoplasms during the study period. . 
Lung tumors were more common in males (82%) than females (18%) and frequently 
observed in the sixth decade. Lung cancer is more common in smokers with a percentage 
of 61.7%.  Among the histological types of lung carcinoma, more than 85% are non small 
cell lung cancer. Squamous cell carcinoma (59.57%) is the most common type of lung 
carcinoma followed by adenocarcinoma (24.46%). EGFR is graded according to the 
percentage of positive tumor cells and the intensity of staining. EGFR expression is 
increased in females with 84.62%, males with a percentage of 47.05%. EGFR expression 
is more commonly seen in adenocarcinoma with a percentage of 47.36% are positive for 
EGFR expression 
 CONCLUSION:  
Vast majority of the lung carcinoma cases present at advanced stage. The 
introduction of targeted therapies particularly tyrosine kinase inhibitors has significantly 
increased progression-free and overall survival in patients those harbor activating EGFR 
mutations. EGFR expression, being a poor prognostic factor, its expression is essential to 
identify the tyrosine kinase inhibitors sensitivity for non small lung carcinomas especially 
adenocarcinoma ,  adenosquamous  carcinoma for better management of the patients. 
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